

Camzyos - Non-PDL
Phone: 215-991-4300
Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:		Prescriber Name:	
HPP Member Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Member Primary Phone:	NPI:	PA PROMISe ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:		
Line of Business: <input type="checkbox"/> Medicaid <input type="checkbox"/> CHIP	Specialty Pharmacy (if applicable):		
Drug Name:	Strength:		
Quantity:	Refills:		
Directions:			
Diagnosis Code:	Diagnosis:		
<i>HPP's maximum approval time is 12 months but may be less depending on the drug.</i>			

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Q1. Is this a renewal request? If no, go to question 5.

 Yes

 No

Q2. Is there attached documentation showing clinical benefit from baseline as evidenced by improvement in symptoms associated with New York Heart Association (NYHA) class II or class III obstructive hypertrophic cardiomyopathy (oHCM) OR that the NYHA is not worsening from baseline?

 Yes

 No

Q3. Does the patient have a left ventricular ejection fraction (LVEF) greater than or equal to (>=) to 50%?

 Yes

 No

Q4. Is the Camzyos (mavacamten) being prescribed at an FDA-approved dose?

 Yes

 No

Q5. Is Camzyos® (mavacamten) being prescribed by or in consultation with a cardiologist?

 Yes

 No

Camzyos - Non-PDL
Phone: 215-991-4300
Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:	Prescriber Name:
<p>Q6. Is the patient greater than or equal to 18 years of age?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>	
<p>Q7. Are clinical notes attached that document a confirmed diagnosis of symptomatic New York Heart Association (NYHA) class II or class III obstructive hypertrophic cardiomyopathy (oHCM), noting associated symptoms? [for example: NYHA Functional Classification – class / symptoms: Class II - Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain AND Class III - Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain.]</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>	
<p>Q8. Does a recent echocardiogram assessment show left ventricular ejection fraction (LVEF) greater than or equal (\geq) to 55%?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>	
<p>Q9. Does the patient have a peak left ventricular outflow tract (LVOT) gradient greater than or equal (\geq) to 50 mmHg at rest or with provocation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>	
<p>Q10. Is there a documented history attached supporting trial and failure, contraindication or intolerance to a non-vasodilating beta blocker (such as metoprolol succinate, nadolol).</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>	
<p>Q11. Is there a documented history attached supporting trial and failure to at least one of the agents types below OR an intolerance to both agents below OR contraindication to both agents below:</p> <p>a) Non-dihydropyridine calcium channel blockers (such as verapamil er, diltiazem er) OR, b) Disopyramide</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>	
<p>Q12. Have other disorders that cause cardiac hypertrophy been ruled out (such as, cardiac amyloidosis, Fabry disease, Noonan syndrome)?</p>	

Camzyos - Non-PDL**Phone: 215-991-4300****Fax back to: 866-240-3712**

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:	Prescriber Name:
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q13. Is the drug being prescribed at an FDA-approved dose?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q14. Will the patient be taking Camzyos® (mavacamten) with moderate to strong CYP2C19 inhibitors or inducers or strong CYP3A4 inhibitors or moderate to strong CYP3A4 inducers?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q15. Additional Information:	

Prescriber Signature_____
Date

v2025